These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 26361173)

  • 1. Risk of HIV and Hepatitis B and C Over Time Among Men Who Inject Image and Performance Enhancing Drugs in England and Wales: Results From Cross-Sectional Prevalence Surveys, 1992-2013.
    Hope VD; Harris R; McVeigh J; Cullen KJ; Smith J; Parry JV; DeAngelis D; Ncube F
    J Acquir Immune Defic Syndr; 2016 Mar; 71(3):331-7. PubMed ID: 26361173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and risk factors associated with HIV/hepatitis B and HIV/hepatitis C co-infections among people who inject drugs in Mozambique.
    Semá Baltazar C; Boothe M; Kellogg T; Ricardo P; Sathane I; Fazito E; Raymond HF; Temmerman M; Luchters S
    BMC Public Health; 2020 Jun; 20(1):851. PubMed ID: 32493347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis B, hepatitis C and HIV prevalence and related sexual and substance use risk practices among key populations who access HIV prevention, treatment and related services in South Africa: findings from a seven-city cross-sectional survey (2017).
    Scheibe A; Young K; Versfeld A; Spearman CW; Sonderup MW; Prabdial-Sing N; Puren A; Hausler H
    BMC Infect Dis; 2020 Sep; 20(1):655. PubMed ID: 32894072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigating the sociodemographic and behavioural factors associated with hepatitis C virus testing amongst people who inject drugs in England, Wales and Northern Ireland: A quantitative cross-sectional analysis.
    Yuan JM; Croxford S; Viviani L; Emanuel E; Phipps E; Desai M
    Int J Drug Policy; 2022 Nov; 109():103821. PubMed ID: 35994940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance and image enhancing drug injectors' access to needle syringe programs: Responding to a public policy dilemma.
    van Beek I; Chronister KJ
    Int J Drug Policy; 2015 Sep; 26(9):868-74. PubMed ID: 26118797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk and blood-borne virus testing among men who inject image and performance enhancing drugs, Sydney, Australia.
    Rowe R; Berger I; Yaseen B; Copeland J
    Drug Alcohol Rev; 2017 Sep; 36(5):658-666. PubMed ID: 28244160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with hepatitis C and HIV testing uptake among men who inject image and performance enhancing drugs.
    Hope VD; McVeigh J; Begley E; Glass R; Edmundson C; Heinsbroek E; Kean J; Campbell J; Whitfield M; Morgan G; Acreman D; Smith J
    Drug Alcohol Rev; 2021 May; 40(4):586-596. PubMed ID: 33164293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secondary distribution of injecting equipment obtained from needle and syringe programmes by people injecting image and performance enhancing drugs: England and Wales, 2012-15.
    Glass R; Hope VD; Njoroge J; Edmundson C; Smith J; McVeigh J; Parry J; Desai M
    Drug Alcohol Depend; 2019 Feb; 195():40-44. PubMed ID: 30580202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High regional variability of HIV, HCV and injecting risks among people who inject drugs in Poland: comparing a cross-sectional bio-behavioural study with case-based surveillance.
    Rosińska M; Sierosławski J; Wiessing L
    BMC Infect Dis; 2015 Feb; 15():83. PubMed ID: 25879904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of, and risk factors for, HIV, hepatitis B and C infections among men who inject image and performance enhancing drugs: a cross-sectional study.
    Hope VD; McVeigh J; Marongiu A; Evans-Brown M; Smith J; Kimergård A; Croxford S; Beynon CM; Parry JV; Bellis MA; Ncube F
    BMJ Open; 2013 Sep; 3(9):e003207. PubMed ID: 24030866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HCV prevalence and risk behaviours among injectors of new psychoactive substances in a risk environment in Hungary-An expanding public health burden.
    Tarján A; Dudás M; Wiessing L; Horváth G; Rusvai E; Tresó B; Csohán Á
    Int J Drug Policy; 2017 Mar; 41():1-7. PubMed ID: 27984762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiology of HIV and hepatitis C infection among women who inject drugs in Northeast India: a respondent-driven sampling study.
    McFall AM; Solomon SS; Lucas GM; Celentano DD; Srikrishnan AK; Kumar MS; Mehta SH
    Addiction; 2017 Aug; 112(8):1480-1487. PubMed ID: 28317210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low levels of hepatitis C diagnosis and testing uptake among people who inject image and performance enhancing drugs in England and Wales, 2012-15.
    Hope VD; McVeigh J; Smith J; Glass R; Njoroge J; Tanner C; Parry JV; Ncube F; Desai M
    Drug Alcohol Depend; 2017 Oct; 179():83-86. PubMed ID: 28759821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Male IDUs who have sex with men in England, Wales and Northern Ireland: are they at greater risk of bloodborne virus infection and harm than those who only have sex with women?
    Marongiu A; Hope VD; Parry JV; Ncube F
    Sex Transm Infect; 2012 Oct; 88(6):456-61. PubMed ID: 22628667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High prevalence of HIV, HBsAg and anti-HCV positivity among people who injected drugs: results of the first bio-behavioral survey using respondent-driven sampling in two urban areas in Mozambique.
    Semá Baltazar C; Horth R; Boothe M; Sathane I; Young P; Chitsondzo Langa D; Condula M; Ricardo H; Dengo Baloi L; Cummings B; Schaad N; Gouveia L; Teodoro E; Raymond HF
    BMC Infect Dis; 2019 Dec; 19(1):1022. PubMed ID: 31791273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding hepatitis B, hepatitis C and HIV among people who inject drugs in South Africa: findings from a three-city cross-sectional survey.
    Scheibe A; Young K; Moses L; Basson RL; Versfeld A; Spearman CW; Sonderup MW; Prabdial-Sing N; Manamela J; Puren AJ; Rebe K; Hausler H
    Harm Reduct J; 2019 Apr; 16(1):28. PubMed ID: 30975139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of HIV and other infections and injection behaviours among people who inject drugs in Addis Ababa, Ethiopia.
    Demissie M; Johnston LG; Muleta M; Desyebelew D; Belete W; G/Egxiabehre A; Gezahegn N; Kassa D; Aseffa Y
    Afr J AIDS Res; 2018 Sep; 17(3):259-264. PubMed ID: 30319040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk correlates of prevalent HIV, hepatitis B virus, and hepatitis C virus infections among noninjecting heroin users.
    Gyarmathy VA; Neaigus A; Miller M; Friedman SR; Des Jarlais DC
    J Acquir Immune Defic Syndr; 2002 Aug; 30(4):448-56. PubMed ID: 12138352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High Prevalence and Incidence of HIV and HCV Among New Injecting Drug Users With a Large Proportion of Migrants--Is Prevention Failing?
    Folch C; Casabona J; Espelt A; Majó X; Meroño M; Gonzalez V; Wiessing L; Colom J; Brugal MT;
    Subst Use Misuse; 2016 Jan; 51(2):250-60. PubMed ID: 26820260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review.
    Degenhardt L; Peacock A; Colledge S; Leung J; Grebely J; Vickerman P; Stone J; Cunningham EB; Trickey A; Dumchev K; Lynskey M; Griffiths P; Mattick RP; Hickman M; Larney S
    Lancet Glob Health; 2017 Dec; 5(12):e1192-e1207. PubMed ID: 29074409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.